American Society of Hirudotherapy

Cutaneous Lichen Planus (Localized)

Investigational use for localized cutaneous lichen planus refractory to topical corticosteroid; very limited case-report evidence.

Tier C — InvestigationalInvestigationalLast updated: 2026-05-26 · Reviewed by ASH Editorial Board

Patient Summary

Is this FDA-cleared for this use?
Not FDA-cleared for lichen planus. FDA cleared medicinal leeches only for venous congestion in microsurgical reconstruction (K040187, 2004). Use for lichen planus is investigational.
What evidence exists?
Tier C (investigational). Only case-report-level evidence; there are no randomized controlled trials. Evidence-based therapy for localized cutaneous lichen planus is potent topical corticosteroid (clobetasol 0.05 percent), topical calcineurin inhibitors (tacrolimus, pimecrolimus), and intralesional triamcinolone for hypertrophic lesions. Phototherapy (narrow-band UVB, PUVA) and systemic agents (acitretin, hydroxychloroquine, methotrexate) are used for widespread or recalcitrant disease. Oral, genital, and erosive subtypes require dermatologic specialty care.
Main risks
  • Bleeding from bite sites for 6 to 24 hours after detachment
  • Bruising and tenderness at the application area for 5 to 10 days
  • Local skin infection or, rarely, Aeromonas infection
  • Allergic reaction to leech saliva (uncommon)
  • Koebner phenomenon (new lichen-planus lesions at bite sites in actively flaring disease)
  • Post-inflammatory hyperpigmentation, especially in darker Fitzpatrick skin types
  • Small permanent scars at bite sites
  • Delay or replacement of evidence-based topical or systemic therapy
Who should not consider this
  • Patients with oral, genital, or erosive lichen planus subtypes
  • Patients with active hepatitis C co-infection without hepatology management
  • Patients with suspected lichenoid drug eruption (taper the offending medication first)
  • Patients with weeping, eroded, or actively flaring lesions
  • Patients on anticoagulants, with hemophilia, or with severe anemia
  • Patients who have not tried first-line topical or intralesional corticosteroid
What to ask your clinician
  • Has the diagnosis been confirmed by biopsy, especially if other diagnoses are possible?
  • Have I been screened for hepatitis C (associated in some populations)?
  • Is this a drug-induced lichenoid reaction (review all medications)?
  • Have I tried potent topical corticosteroid (clobetasol) or intralesional triamcinolone?
  • If widespread, am I a candidate for phototherapy (NB-UVB) or systemic therapy?
  • What evidence supports leech therapy for lichen planus specifically?
  • What is the practitioner's experience and Aeromonas-prevention plan?
When to seek urgent care
  • Painful or rapidly enlarging mouth, throat, or genital ulcers (mucosal lichen planus — needs specialty care)
  • Difficulty swallowing or hoarseness (esophageal or laryngeal involvement)
  • Severe vulvovaginal or penile pain, scarring, or new urinary symptoms
  • Spreading redness, warmth, pus, or red streaks (cellulitis)
  • Bleeding from a bite site lasting more than 24 to 48 hours
  • Fever above 38.0 C / 100.4 F or chills
  • Hives, throat tightness, or breathing difficulty

What this does NOT mean

  • This is not FDA-cleared for lichen planus.
  • Case reports do NOT establish efficacy versus topical / intralesional corticosteroid, calcineurin inhibitors, or phototherapy.
  • Mechanism rationale does NOT establish clinical efficacy.
  • Oral, genital, and erosive lichen planus REQUIRE dermatologic specialty care — leech therapy is not appropriate.
  • Leech therapy is not a substitute for evidence-based therapy.

Clinical Profile

Category
dermatological
ICD-10
L43.0, L43.1, L43.2, L43.3, L43.8, L43.9
Safety tier
medium

Evidence Summary

Localized cutaneous lichen planus is conventionally treated with potent topical corticosteroid, topical calcineurin inhibitors, and intralesional steroid for hypertrophic lesions. Phototherapy and systemic agents (acitretin, hydroxychloroquine, methotrexate) are reserved for widespread or recalcitrant disease. No controlled trial or case report shows leech therapy improving lichen planus; use for this indication is not supported. In fact, lichen planus is a Koebner-positive (trauma-triggered) disease, and there is a published case of lichen planus arising after hirudotherapy, meaning leech application is a reported potential trigger rather than a treatment. Oral, genital, and erosive variants require dermatologic specialty care.

Treatment specifics

How many leeches, where they are placed, how long a session lasts, and whether to repeat are clinical decisions made by a qualified provider under institutional protocol — not something to self-administer. Discuss the specifics with a clinician experienced in medicinal leech therapy. (Clinicians: switch the audience selector in the top bar to “Clinician” to view protocol detail.)

Key Trials

  1. Verma S et al. (2021)0

Contraindications

  • Active anticoagulant therapy (warfarin INR >2.0, DOACs, heparin)
  • Hemophilia or other bleeding disorder
  • Severe anemia (Hb <10 g/dL)
  • Active bacteremia or sepsis
  • Known hypersensitivity to leech salivary proteins
  • Pregnancy (relative — first/third trimester)
  • Immunocompromised state with severe neutropenia
  • Oral, genital, or erosive lichen planus subtypes
  • Active hepatitis C co-infection without hepatology management
  • Suspected lichenoid drug eruption (taper offending agent first)

Related Conditions

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.

Cutaneous Lichen Planus (Localized) — Hirudotherapy Evidence | ASH